Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

46.75 +0.94 (+2.05%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
74 75 Next >
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund? 
Via The Motley Fool
Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom
The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic CRC showcase promising clinical activity. 
Via Benzinga
Peering Into Bristol-Myers Squibb's Recent Short Interest
Via Benzinga
Wall Street Favorites: 3 Warren Buffett Stocks With Strong Buy Ratings for April 2024
If you’re wondering where to invest in a stock picker's market, these three Warren Buffett stocks are a good place to start. 
Via InvestorPlace
This Is What Whales Are Betting On Bristol-Myers Squibb
Via Benzinga
If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names
Capitalize on the biotech sector's boom with these three top biotech stocks to buy, driven by aging demographics and advanced treatments. 
Via InvestorPlace
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease. 
Via InvestorPlace
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE: 
Via Benzinga
2 High-Yield Dividend Stocks Billionaires Are Buying Hand Over Fist
These reliable dividend payers offer yields of 3.3% and better at recent prices. 
Via The Motley Fool
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
Income-seeking investors can look forward to steady payout raises from these pharma stocks. 
Via The Motley Fool
Bristol Myers Squibb's Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain Mutation
Bristol Myers Squibb's latest data on Krazati (adagrasib) in combination with cetuximab for KRASG12C-mutated colorectal cancer. Promising objective response rates and progression-free survival. FDA... 
Via Benzinga
Exposures Product Safety
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
From Bristol Myers Squibb
Via Business Wire
Bristol Myers' $14B Bet On Schizophrenia - Drug Cuts Symptoms Without Common Side Effect Of Weight Gain Associated With Other Antipsychotics
Interim data from Bristol Myers Squibb's Phase 3 EMERGENT program on KarXT's safety, tolerability, and metabolic outcomes in adults with schizophrenia. Find out how KarXT demonstrated favorable impacts... 
Via Benzinga
Down 75%. Is Agenus Stock a Buy on the Dip?
Wall Street analysts who watch the cancer drug developer closely think it could rocket higher. 
Via The Motley Fool
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates... 
Via Talk Markets
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
From Bristol Myers Squibb
Via Business Wire
The 3 Most Undervalued Biotech Stocks to Buy in April 2024
The most undervalued biotech stocks to buy in April are intriguing value options with mature biotech plays that boast impressive pipelines. 
Via InvestorPlace
FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer
FDA approves Bristol-Myers Squibb and 2seventy Bio Abecma (ide-cel) for relapsed or refractory multiple myeloma after ≥2 prior therapies. Extends progression-free survival by 13.3 months vs. standard... 
Via Benzinga
Exposures Product Safety
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
From Bristol Myers Squibb
Via Business Wire
2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?
These stocks could rocket higher, but they also present significant risks. 
Via The Motley Fool
European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
From Bristol Myers Squibb
Via Business Wire
Merger Mania: 3 Potential Takeover Targets to Watch for Lucrative Buyouts
With interest rates poised to fall, acquisitions will become more numerous. Here are three potential takeover targets. 
Via InvestorPlace
Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
From Bristol Myers Squibb
Via Business Wire
The Bargain Hunter’s Dream: 3 Underpriced Stocks Poised for Massive Gains
Uncover strategic moves by three pharma giants poised to capture trends and fulfill emerging healthcare needs. 
Via InvestorPlace
One Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details
Bristol Myers Squibb shares update on Phase 3 YELLOWSTONE trial for Zeposia (ozanimod) in Crohn's disease. Primary endpoint not met, safety consistent. Also, positive Phase 3 results for Krazati... 
Via Benzinga
The 3 Best Biotech Stocks to Buy in Q2 2024
Biotech can be a risky industry for investors, but we've done the legwork for you with these three biotech stocks for Q2. 
Via InvestorPlace
Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung…
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
From Bristol Myers Squibb
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback